{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T17:49:47Z","timestamp":1789148987388,"version":"build-2803163510"},"reference-count":18,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["Indian J Dermatol Venereol Leprol"],"abstract":"<jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Granuloma annulare (GA) is a necrobiotic granulomatous disorder that may sometimes be resistant to treatment, especially the generalised form. Tofacitinib has recently shown promise in the treatment of non-infective granulomatous dermatosis.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives<\/jats:title>\n<jats:p>In this study, we aimed to evaluate the response of generalised GA to oral tofacitinib.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective case series in patients of generalised GA who were treated with oral tofacitinib 5 mg twice a day in a tertiary care centre in north India. Baseline clinical details and histopathological findings were reviewed. Treatment response was noted in the form of clearance of lesions (complete or partial) along with the time taken to achieve the maximum response.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 15 patients of generalised GA were included in this study, amongst whom nine patients were resistant to conventional therapies whilst the remaining were treatment na\u00efve. Complete clearance of lesions was noted in 11 patients at a mean treatment duration of 4.4 \u00b1 2.1 months whereas clearance was partial in four, with a mean follow-up duration post- treatment in patients who had partial clearance, which is 7.3 \u00b1 2.8 month, with a reduction in erythema and infiltration in those lesions. Adverse effects in the form of hyperlipidemia were observed in two patients.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Tofacitinib, a JAK-STAT inhibitor is beneficial in treating GA, especially in those with generalised and recalcitrant disease.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/ijdvl_215_2024","type":"journal-article","created":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T09:26:01Z","timestamp":1721467561000},"page":"65-70","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Therapeutic success of tofacitinib in granuloma annulare: A retrospective case series of 15 patients"],"prefix":"10.25259","volume":"91","author":[{"given":"Anubha","family":"Dev","sequence":"first","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Keshavamurthy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Leprology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debajyoti","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Pathology, PGIMER, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2024,7,20]]},"reference":[{"key":"10.25259\/IJDVL_215_2024\/ref-1","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2015.03.054","article-title":"Granuloma annulare: Clinical and histologic variants, epidemiology, and genetics","volume":"75","author":"Piette","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.jaad.2015.03.055","article-title":"Granuloma annulare: Pathogenesis, disease associations and triggers, and therapeutic options","volume":"75","author":"Piette","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s40257-021-00636-1","article-title":"Granuloma annulare: An updated review of epidemiology, pathogenesis, and treatment options","volume":"23","author":"Joshi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-4","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1001\/jamadermatol.2021.1847","article-title":"Incidence and prevalence of granuloma annulare in the United States","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-5","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15832","article-title":"Prevalence of granuloma annulare in the United States: A cross\u2010sectional study in the all of us research program","volume":"61","author":"Leasure","year":"2022","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-6","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/s0190-9622(89)70005-0","article-title":"Generalized granuloma annulare: Clinical and laboratory findings in 100 patients","volume":"20","author":"Dabski","year":"1989","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamadermatol.2021.1805","article-title":"Association of granuloma annulare with type 2 diabetes, hyperlipidemia, autoimmune disorders, and hematologic malignant neoplasms","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-8","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1001\/jamadermatol.2019.2130","article-title":"Refractory generalized granuloma annulare treated with oral apremilast","volume":"155","author":"Bishnoi","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-9","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/j.jaci.2020.10.012","article-title":"Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib","volume":"147","author":"Wang","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"10.25259\/IJDVL_215_2024\/ref-10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jaad.2019.12.028","article-title":"Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways","volume":"83","author":"Min","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.jaad.2019.05.098","article-title":"Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare","volume":"82","author":"Damsky","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/ajd.13875","article-title":"Treatment of granuloma annulare with tofacitinib","volume":"63","author":"Bosch\u2010Amate","year":"2022","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jdcr.2019.10.016","article-title":"Treatment of granuloma annulare with tofacitinib 2% ointment","volume":"6","author":"Damsky","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_215_2024\/ref-14","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1016\/j.jdcr.2020.07.054","article-title":"Generalized granuloma annulare: A widespread response to limited application of compounded 2% topical tofacitinib","volume":"6","author":"Durgin","year":"2020","journal-title":"JAAD Case Rep"},{"key":"10.25259\/IJDVL_215_2024\/ref-15","first-page":"102","article-title":"Granuloma annulare: A retrospective series of 133 patients","volume":"103","author":"Rubin","year":"2019","journal-title":"Cutis"},{"key":"10.25259\/IJDVL_215_2024\/ref-16","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaad.2021.07.037","article-title":"Methotrexate for generalized granuloma annulare: A 60% response rate in a retrospective case series of 15 patients","volume":"87","author":"Hrin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-17","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/ijd.14350","article-title":"The role of biologics in the treatment of chronic granuloma annulare","volume":"58","author":"Chen","year":"2019","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_215_2024\/ref-18","doi-asserted-by":"publisher","first-page":"2050313X2110394","DOI":"10.1177\/2050313X211039477","article-title":"Improvement of granulomatous skin conditions with tofacitinib in three patients: A case report","volume":"9","author":"McPhie","year":"2021","journal-title":"SAGE Open Med Case Rep"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/therapeutic-success-of-tofacitinib-in-granuloma-annulare-a-retrospective-case-series-of-15-patients\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/therapeutic-success-of-tofacitinib-in-granuloma-annulare-a-retrospective-case-series-of-15-patients\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T11:31:41Z","timestamp":1735039901000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/therapeutic-success-of-tofacitinib-in-granuloma-annulare-a-retrospective-case-series-of-15-patients\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,20]]},"references-count":18,"alternative-id":["10.25259\/IJDVL_215_2024"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_215_2024","relation":{},"ISSN":["0973-3922","0378-6323"],"issn-type":[{"value":"0973-3922","type":"electronic"},{"value":"0378-6323","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7,20]]},"article-number":"65"}}